专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2006104205A Human growth hormone variant 审中-公开
标题翻译：人类生长激素变异
公开(公告)号：JP2006104205A
公开(公告)日：2006-04-20
申请号：JP2005304574
申请日：2005-10-19
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： GARRARD LISA J , HENNER DENNIS J , BASS STEVEN , GREENE RONALD , LOWMAN HENRY B , WELLS JAMES A , MATTHEWS DAVID J
IPC分类号： C07K14/61 , C12N15/09 , A61K38/27 , A61P5/06 , A61P5/10 , C07K14/01 , C07K14/47 , C07K14/475 , C07K14/52 , C07K14/575 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12N7/02 , C12P21/02 , C12Q1/02 , C12R1/19 , G01N33/53
摘要： PROBLEM TO BE SOLVED: To provide human growth hormone variants in the production of a therapeutic or diagnostic compound which imitates a protein or non-peptidyl molecule such as a hormone, a drug, and other small molecules (particularly a biologically active molecule such as a growth hormone). SOLUTION: The human growth hormone variants have (a) the amino acids of hGH at positions 172 and the like which are replaced with (1) other amino acids selected from the group consisting of R, S, F, R and the like, (b) the amino acids at positions 10 and the like which are replaced with (1) other amino acids selected from the group consisting of H, G, N, N and the like, (c) the amino acid at position 174 being serine and the amino acid at position 176 being tyrosine, and the amino acids at positions 167 and the like which are replaced with (1) other amino acids selected from the group consisting of N, S, T, T and the like, (d) glutamate 174 being replaced with tyrosine 174 , phenylalanine 176 being replaced with tyrosine 176 , and 8 amino acids which are replaced with other amino acids, (e) in the hGH variant (d), 8 of amino acid F10 and the like which are replaced with (1) other amino acids selected from the group (1) consisting of H, G, N, N, N, S, T, T and the like in the order named, (f) in the (e), leucine 15 being replaced with arginine 15 and the amino acid at position 168 being replaced with arginine 168 , and (g) the (e) further containing phenylalanine 176 . COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：待解决的问题：提供人生长激素变体在制备模拟蛋白质或非肽基分子如激素，药物和其他小分子（特别是生物活性分子）的治疗或诊断化合物如生长激素）。解决方案：人生长激素变体具有（a）位置172等处的hGH的氨基酸，其被替换为（1）选自R，S，F，R的其它氨基酸，和如（1）选自H，G，N，N等的其它氨基酸，（c）位置10上的氨基酸等位置上的氨基酸，是丝氨酸，第176位的氨基酸是酪氨酸，167位的氨基酸被替换为（1）选自N，S，T，T等的其它氨基酸（ d）用酪氨酸 174 替代谷氨酸酯 174 ，用酪氨酸 176 替代苯丙氨酸 176 和8个氨基酸其被替换为其他氨基酸，（e）在hGH变体（d）中，氨基酸F10等的8等被（1）选自由H，G， N，N，N，S，T，T （f）在（e）中，亮氨酸 15 被精氨酸 15 替代，位置168处的氨基酸被精氨酸 SB> 168 ，和（g）（e）还含有苯丙氨酸 176 。版权所有（C）2006，JPO＆NCIPI

2. 发明专利

JP2005065705A Method for enriching mutant protein having modified bonding property 审中-公开
标题翻译：用于增强具有改性结合性质的突变蛋白的方法
公开(公告)号：JP2005065705A
公开(公告)日：2005-03-17
申请号：JP2004327565
申请日：2004-11-11
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： GARRARD LISA J , HENNER DENNIS J , BASS STEVEN , GREENE RONALD , LOWMAN HENRY B , WELLS JAMES A , MATTHEWS DAVID J
IPC分类号： C12N15/09 , A61K38/27 , A61P5/06 , C07K14/01 , C07K14/47 , C07K14/475 , C07K14/52 , C07K14/575 , C07K14/61 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12N7/02 , C12P21/02 , C12Q1/02 , C12R1/19
摘要： PROBLEM TO BE SOLVED: To provide a phagemid expression vector containing a transcription control element functionally bonded to a gene fusion encoding a fusion protein. SOLUTION: Disclosed is a phagemid expression vector, wherein the gene fusion comprises a first gene encoding a polypeptide and a second gene encoding at least one part of a phage coat protein and wherein (a) the vector contains no gene encoding a mature coat protein and (b) no perfect phage genome, (c) host cell transformation caused by the vector produces no phage particle in the absence of a helper phage, or (d) a DNA triplet codon encoding a termination codon capable of controlling mRNA is inserted between the fusion terminals of the first and the second genes or substituted instead of an amino acid-encoded triplet codon adjacent to the gene fusion connecting point. COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：待解决的问题：提供含有与编码融合蛋白的基因融合物功能结合的转录调控元件的噬菌粒表达载体。解决方案：公开了一种噬菌粒表达载体，其中所述基因融合物包含编码多肽的第一基因和编码噬菌体外壳蛋白的至少一部分的第二基因，其中（a）载体不含编码成熟的基因外壳蛋白和（b）没有完美的噬菌体基因组，（c）由载体引起的宿主细胞转化在不存在辅助噬菌体的情况下不产生噬菌体颗粒，或（d）编码能够控制mRNA的终止密码子的DNA三联密码子是插入在第一和第二基因的融合末端之间，或代替与基因融合连接点相邻的氨基酸编码的三联密码子。版权所有（C）2005，JPO＆NCIPI

3. 发明专利

JP2005021157A Human growth hormone variants 有权
标题翻译：人类生长激素变异
公开(公告)号：JP2005021157A
公开(公告)日：2005-01-27
申请号：JP2004126082
申请日：2004-04-21
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： CUNNINGHAM BRIAN C , LOWMAN HENRY B , WELLS JAMES A , CLARK ROSS G , OLSON KENNETH , FUH GERMAINE G
IPC分类号： C12N15/09 , A61K31/00 , A61K38/00 , A61K38/27 , A61K47/48 , A61P3/00 , A61P3/10 , A61P5/00 , A61P5/08 , A61P5/12 , A61P13/12 , A61P35/00 , A61P37/00 , A61P43/00 , C07K1/107 , C07K14/61 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/18 , C12N15/63 , C12P21/02 , C12R1/19
CPC分类号： C07K14/61 , A61K38/00 , A61K47/60 , C07K2319/00 , Y10S514/866 , Y10S930/12
摘要： PROBLEM TO BE SOLVED: To provide a human growth hormone variant having an enhanced affinity for a growth hormone receptor and also a human growth hormone variant conjugated to one or more chemical groups, such as poly(ethylene glycol), which is believed to prolong the in vivo half-life of the variant. SOLUTION: The human growth hormone variants comprise a plurality of specific amino acid substitutions. The human growth hormone variants are used as agonists or antagonists of human growth hormone. COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：要解决的问题：提供对生长激素受体具有增强亲和力的人生长激素变体，以及与一个或多个化学基团（例如聚（乙二醇））缀合的人生长激素变体，其被认为是以延长变体的体内半衰期。解决方案：人生长激素变体包含多个特定的氨基酸取代。人生长激素变体用作人生长激素的激动剂或拮抗剂。版权所有（C）2005，JPO＆NCIPI

4. 发明专利

JP2004121261A Method for enriching mutant protein having modified bonding property 审中-公开
公开(公告)号：JP2004121261A
公开(公告)日：2004-04-22
申请号：JP2003403062
申请日：2003-12-02
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： GARRARD LISA J , HENNER DENNIS J , BASS STEVEN , GREENE RONALD , LOWMAN HENRY B , WELLS JAMES A , MATTHEWS DAVID J
IPC分类号： C12N15/09 , A61K38/27 , A61P5/06 , C07K14/01 , C07K14/47 , C07K14/475 , C07K14/52 , C07K14/575 , C07K14/61 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12N7/02 , C12P21/02 , C12Q1/02 , C12R1/19
摘要： PROBLEM TO BE SOLVED: To provide a phagemid expression vector containing a transcription control element operatively bonded to a gene fusion encoding a fusion protein. SOLUTION: The phagemid expression vector comprises a gene fusion comprising the first gene encoding polypeptide and the second gene encoding at least one part of a phage coat protein, wherein (a) the vector contains no gene encoding a mature coat protein and (b) no perfect phage genome, (c) host cell transformation caused by the vector produces no phage particle in the absence of a helper phage, or (d) a DNA triplet codon encoding a termination codon capable of controlling mRNA is inserted between the fusion terminals of the first and the second genes or substituted instead of an amino acid-encoded triplet codon adjacent to the gene fusion connecting point. COPYRIGHT: (C)2004,JPO

5. 发明专利

JP2001270837A PHARMACEUTICAL COMPOSITION COMPRISING LIGAND AGONIST AGENT 失效
公开(公告)号：JP2001270837A
公开(公告)日：2001-10-02
申请号：JP2001054464
申请日：2001-02-28
申请人： GENENTECH INC
发明人： CUNNINGHAM BRIAN C , DEVOS ABRAHAM M , MULKERRIN MICHAEL G , ULTSCH MARK , WELLS JAMES A
IPC分类号： A01K67/027 , A61K38/00 , A61K38/04 , A61K39/395 , A61P5/02 , A61P5/06 , A61P43/00 , C07K14/505 , C07K14/52 , C07K14/53 , C07K14/535 , C07K14/54 , C07K14/545 , C07K14/55 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/61 , C07K14/705 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/85 , C12P21/02 , G01N33/15 , G01N33/50 , G01N33/53 , G01N33/542 , G01N33/68 , G01N33/74
摘要： PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition comprising a ligand agonist agent by finding out that a three-element complex is formed from a growth hormone together with its receptors in which a 1:2 complex is produced by initially binding a site 1 on the hormone to one receptor molecule and then binding a hormone site 2 to another receptor molecule. SOLUTION: As a result of studies on the three-element complex, it has been determined that a selected antibody against the receptors of a ligand is capable of acting as the ligand agonist agent or a ligand antagonist agent. New uses related to the new growth hormone and the antigrowth hormone receptor antibody are provided.

6. 发明专利

JP2000184896A HORMONE VARIANT 失效
公开(公告)号：JP2000184896A
公开(公告)日：2000-07-04
申请号：JP2000034866
申请日：2000-02-14
申请人： GENENTECH INC
发明人： WELLS JAMES A , CUNNINGHAM BRIAN C
IPC分类号： G01N33/53 , A61K38/27 , A61P3/10 , A61P5/00 , A61P5/06 , C07K14/00 , C07K14/435 , C07K14/47 , C07K14/575 , C07K14/61 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/10 , C12N15/12 , C12N15/18 , C12N15/62 , C12N15/63 , C12N15/70 , C12P21/02 , C12R1/19 , C40B40/02 , G01N33/68 , G01N33/74
摘要： PROBLEM TO BE SOLVED: To obtain a new growth hormone variant having a naturally non-existing amino acid sequence, having the same first and third portions as those of a parent hormone and the second portion comprising a portion similar to that of the parent hormone, and capable of interacting with a target substance different from the parent hormone. SOLUTION: This new growth hormone variant differently interacts with a target substance in comparison with a parent growth hormone, has an amino acid sequence not existing in the nature, and comprises at least the first, second and third portions sequentially from the N-terminal. The first portion corresponds to at least a part of the amino acid sequence of a parent growth hormone occurring in the nature, and the third portion corresponds to at least a part of the amino acid sequence of a parent growth hormone. The second portion corresponds to the similar portion of the amino acid sequence of a natural growth hormone similar to the parent growth hormone. The growth hormone variant has desirable biological, biochemical and immunological properties which are different from those of the original growth hormone. The variant is obtained by inducing a mutation in a growth hormone gene, inserting the mutated gene into a vector and then expressing the growth hormone variant in a host cell.

7. 发明专利

JP2003159061A LIGAND AGONIST 审中-公开
公开(公告)号：JP2003159061A
公开(公告)日：2003-06-03
申请号：JP2002271918
申请日：2002-09-18
申请人： GENENTECH INC
发明人： CUNNINGHAM BRIAN C , DEVOS ABRAHAM M , MULKERRIN MICHAEL G , ULTSCH MARK , WELLS JAMES A
IPC分类号： A01K67/027 , A61K38/00 , A61K38/04 , A61K39/395 , A61P5/02 , A61P5/06 , A61P43/00 , C07K14/505 , C07K14/52 , C07K14/53 , C07K14/535 , C07K14/54 , C07K14/545 , C07K14/55 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/61 , C07K14/705 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/85 , C12P21/02 , G01N33/15 , G01N33/50 , G01N33/53 , G01N33/542 , G01N33/68 , G01N33/74
摘要： PROBLEM TO BE SOLVED: To provide any one variant of a growth hormone, a placental lactogen or a prolactin which is a monomer polypeptide hormone containing 4 amphipathic alpha helices. SOLUTION: This agonist is obtained by forming a ternary complex from the growth hormone and its receptors, initially binding site 1 on the hormone to one receptor molecule, then binding site 2 to another receptor molecule and thereby producing a 1:2 complex. COPYRIGHT: (C)2003,JPO

8. 发明专利

JP2002136295A HUMAN GROWTH HORMONE VARIANT 审中-公开
公开(公告)号：JP2002136295A
公开(公告)日：2002-05-14
申请号：JP2001256932
申请日：2001-08-27
申请人： GENENTECH INC
发明人： GARRARD LISA J , HENNER DENNIS J , BASS STEVEN , GREENE RONALD , LOWMAN HENRY B , WELLS JAMES A , MATTHEWS DAVID J
IPC分类号： C12N15/09 , A61K38/27 , A61P5/06 , C07K14/01 , C07K14/47 , C07K14/475 , C07K14/52 , C07K14/575 , C07K14/61 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12N7/02 , C12P21/02 , C12Q1/02 , C12R1/19
摘要： PROBLEM TO BE SOLVED: To produce a therapeutic or diagnostic compound imitating a protein or a non-peptidyl molecule such as a hormone, a medicine or one of other small molecules (especially, a biologically active molecule such as a growth hormone). SOLUTION: This human growth hormone variant is selected from the following group: (a) 172 of hGH amino acid is selected from the group consisting of R, S, F, R, and the like; (b) each of an amino acids 10... is selected from the group consisting of H, G, N, N, and the like; (c) 174 of the amino acid is serine; 176 is tyrosine; and 167 is selected from the group (1) N, S, T, T and the like; (d) glutamate174 is replaced with serine174; phenylalamine176 is replaced with tyrosine176; and eight amino acids are replaced; (e) eight amino acids F10... in hGH variant of (d) are sequentially selected from (1) H, G, N, N, N, S, T, T, and the like; (f) (e) is replaced with arginine168 and leucine15 replaced with arginine15; and (g) (e) further contains phenylalanine176.

9. 发明专利

JP2002119294A METHOD FOR ENRICHING MUTANT PROTEIN HAVING MODIFIED BONDING PROPERTY 审中-公开
公开(公告)号：JP2002119294A
公开(公告)日：2002-04-23
申请号：JP2001256931
申请日：2001-08-27
申请人： GENENTECH INC
发明人： GARRARD LISA J , HENNER DENNIS J , BASS STEVEN , GREENE RONALD , LOWMAN HENRY B , WELLS JAMES A , MATTHEWS DAVID J
IPC分类号： C12N15/09 , A61K38/27 , A61P5/06 , C07K14/01 , C07K14/47 , C07K14/475 , C07K14/52 , C07K14/575 , C07K14/61 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12N7/02 , C12P21/02 , C12Q1/02 , C12R1/19
摘要： PROBLEM TO BE SOLVED: To provide a phagemid expression vector containing a transcription control element operatively bonded to a fusion gene encoding a fusion protein. SOLUTION: The invention provides a phagemid expression vector containing a fusion gene comprising the first gene encoding polypeptide and the second gene encoding at least one part of a phage coat protein, and comprising (a) not containing a gene encoding a mature coat protein, (b) not containing a perfect phage genome, (c) not producing a phage particle in the absence of a helper phage in transformation of a host cell by the vector, or (d) that a DNA triplet codon encoding a termination codon capable of controlling mRNA is inserted into between the fusion terminals of the first and the second genes or substituted in stead of an amino acid-encoded triplet codon adjacent to the fusion connecting point of the gene.

10. 发明申请

WO9845331A3 ANTI-VEGF ANTIBODIES 审中-公开
标题翻译：抗VEGF抗体
公开(公告)号：WO9845331A3
公开(公告)日：1998-12-03
申请号：PCT/US9806604
申请日：1998-04-03
申请人： GENENTECH INC , BACA MANUEL , WELLS JAMES A , PRESTA LEONARD G , LOWMAN HENRY B , CHEN YVONNE MAN YEE
发明人： BACA MANUEL , WELLS JAMES A , PRESTA LEONARD G , LOWMAN HENRY B , CHEN YVONNE MAN-YEE
IPC分类号： C12N15/09 , A61K38/00 , A61K38/17 , A61K39/395 , A61P25/00 , A61P27/02 , A61P35/00 , C07K16/18 , C07K16/22 , C07K16/46 , C12N5/10 , C12N15/02 , C12N15/13 , C12N15/66 , C12P21/02 , C12P21/08 , C07K16/00
CPC分类号： C07K16/22 , A61K38/00 , C07K16/005 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/73 , C07K2317/92
摘要： Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro, and inhibit tumor growth in vivo.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式